Yelak Biru | CureTalks
Yelak is an Information technology director for a fortune 50 global CPG company. He is also myeloma patient and advocate. Diagnosed with stage III myeloma at a young age of 25, Yelak was given 2-3 years to live. Two decades later, he continues to share the hope of living with myeloma by respecting the past, understanding the present and being energized by the future. Yelak is a member of the International Myeloma Foundation board of directors, a past speaker at EHA on Relapsed and Refractory myeloma, a facilitator at smartpatients.com, a member of the Global Myeloma Action network and an attendee of ASH since 2006. You can follow Yelak on twitter @NorthTxMSG
Related Talks
Latest Advances in Myeloma Treatment: ASCO and EHA 2018 Highlights
The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient…
Targeting Stem Cells in Multiple Myeloma for Improved Outcomes
Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal…
Demystifying Stem Cell Transplant for Multiple Myeloma Treatment
In 2017 stem cell transplants remains a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done…
Immunotherapy Advances in Multiple Myeloma
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody…
Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention.…